Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elezanumab in acute traumatic cervical spinal cord injury
MOH_2022-05-24_010719Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute cervical spinal cord injury (ACSCI) comparing Elezanumab with Placebo (2 arms). Primary endpoints: Change in upper extremity motor score and Safety of elezanumab. Started May 2022; status: completed.
02
Drugs
elezanumab
03
Conditions
acute cervical spinal cord injury (ACSCI)
Beyond the preview
Go deeper on MOH_2022-05-24_010719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-24_010719.